^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    DNA topoisomerase inhibitor

    Related drugs:
    Apply
    A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors (NCT05830097)
    Phase 1/2
    Coherent Biopharma (Hefei) Co., Ltd.
    Recruiting
    Last update posted :
    12/12/2023
    Initiation :
    03/14/2023
    Primary completion :
    06/30/2025
    Completion :
    09/30/2025
    FOLR1 • TRPV6
    |
    CBP-1019
    Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation (PRECISIONV) (NCT00261378)
    Phase 2
    Boston Scientific Corporation
    Completed
    Last update posted :
    07/21/2021
    Initiation :
    11/01/2005
    Primary completion :
    01/01/2008
    Completion :
    01/01/2008
    AFP
    |
    DC Bead (E7040)
    A Study to Evaluate the Safety, Tolerability and Immunogenicity of EGFR(V)-EDV-Dox in Subjects With Recurrent Glioblastoma Multiforme (GBM) (CerebralEDV) (NCT02766699)
    Phase 1
    Engeneic Pty Limited
    Unknown status
    Last update posted :
    08/29/2019
    Initiation :
    10/25/2016
    Primary completion :
    12/01/2019
    Completion :
    06/01/2020
    EGFR
    |
    Vectibix (panitumumab) • doxorubicin hydrochloride • doxorubicin encapsulated nanocells (EGFREDVDox)
    Irinotecan -Eluting LC Bead-M1 (DEBIRI-M1) for Patients With Liver Metastases From Colorectal Cancer (NCT02015754)
    Phase 2
    Yale University
    Completed
    Last update posted :
    03/22/2018
    Initiation :
    02/01/2014
    Primary completion :
    06/02/2015
    Completion :
    12/13/2016
    CEACAM5
    |
    irinotecan • DC Bead (E7040)
    DA Versus DAC as Postoperative Adjuvant Treatment for Early-stage Breast Cancer (NCT02838225)
    Phase 2
    Peking Union Medical College Hospital
    Completed
    Last update posted :
    07/20/2016
    Initiation :
    01/01/2009
    Primary completion :
    01/01/2016
    HER-2
    |
    paclitaxel • docetaxel • doxorubicin hydrochloride • cyclophosphamide • Pinorubin (pirarubicin) • cyclophosphamide intravenous